SEC Form 4 · accession 0001358403-18-000075
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M. Spencer
Officer — Chief Technology Officer
Period of report
Jul 2, 2018
Accepted (ET)
Jul 5, 2018 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.72 | Jul 2, 2018 | A | 42,000 | A | — | Jul 1, 2028 | Common Stock | 42,000 | 42,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.